logo-loader

Creo Medical Group "really pleased" with first human trial of lung lesion treatment

Published: 09:18 26 May 2023 EDT

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after announcing the successful completion of a first human trial of its pioneering MicroBlate Flex device for soft tissue lung lesion microwave ablation.

Gulliford reveals the difference he believes the product could ultimately make to people suffering from early-stage lung cancer, saying that he's "really pleased that we've had a great outcome so far."

Alvopetro posts 86% net back margin as Q2 volumes jump 26% and Murucututu...

Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) CEO Corey Ruttan tells Proactive's Stephen Gunnion that Q2 2026 sales volumes averaged 3,067 barrels of oil equivalent per day, up 26% year-on-year, with revenue of just over $19 million and funds flow from operations of $14.1...

23 hours, 2 minutes ago